Degenerative myopia

This study tested a drug called faricimab (VABYSMO®) against an existing treatment (ranibizumab) for people with vision loss caused by abnormal blood vessels growing in the back of the eye due to severe nearsightedness. The trial involved 280 participants who received either fari…

This study tested three low doses of atropine eye drops (0.01%, 0.03%, and 0.05%) in 95 children aged 6–18 with nearsightedness. The goal was to see which dose best slowed the worsening of myopia with the fewest side effects. Over 18 months, the 0.05% dose worked best at controll…

This study looked at whether adding bifocal glasses to daily atropine eye drops works better than atropine alone to slow down nearsightedness (myopia) in children. 210 kids aged 4-16 with worsening myopia took part. The main goal was to measure changes in their vision prescriptio…

This study tested three strengths of atropine eye drops (0.01%, 0.04%, and 0.1%) in 219 children with high myopia (severe nearsightedness). The goal was to see which dose best slows the worsening of vision and eye growth over two years. Children received one drop in each eye ever…

This study tested whether combining low-dose atropine eye drops with special soft contact lenses can slow the progression of high myopia (severe nearsightedness) in children aged 6-12. 120 children were split into three groups: one got the combo therapy, one got atropine alone wi…

This trial asks whether using a 3D visualization system during cataract surgery helps surgeons operate more smoothly in people with high myopia (very nearsighted eyes). It compares the 3D system to a traditional optical microscope, measuring how often the surgeon needs to adjust …

This study examined 39 people with severe nearsightedness to see if lower levels of a natural eye pigment (macular pigment) are linked to tiny cracks in the back of the eye called lacquer cracks. These cracks can lead to vision loss. The researchers measured the pigment's optical…